[Floxuridine-containing regime in the treatment of gestational trophoblastic tumor].
OBJECTIVE
To analyse the efficacy of the floxuridine (FUDR)-containing regime (single agent or in combination) in the treatment of gestational trophoblastic tumor.


METHODS
Seventy-four patients with gestational trophoblastic tumors (GTT), 47 invasive mole and 27 choriocarcinoma, were treated with FUDR-containing regime. The clinical staging of the disease were: 33 cases of stage I, 3 cases of stage II, 31 cases of stage IIIa, 6 cases of stage IIIb, and 1 case of stage IV.


RESULTS
The cure rate of FUDR-containing regime in the treatment of GTT was 91.9% (68 out of 74 cases). Twenty-one out of these 74 patients showed drug resistant to 5-FU-containing or MTX-containing regime and were cured after they changed to the FUDR-containing regime. All 7 patients of advanced stage (> or = III b) got cured. The major adverse event of FUDR-containing regime was myelodepression and gastrointestinal toxicity: III-IV degree granulopenia 26%, III-IV thrombopenia 6.2%, III degree vomiting 57.1%, and III degree diarrhea 4.3%.


CONCLUSIONS
FUDR-containing regime is efficient for the treatment of GTT, even for those with advanced stage or drug-resistant disease.
Wan
Xi-run
XR
Department of Obstetrics and Gynecology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China. wanxr@hotmail.com
Yang
Xiu-yu
XY
Xiang
Yang
Y
Wu
Yu
Y
Yang
Yan-mei
YM
Yin
Shu-jie
SJ
Li
Jie
J
D000293:Adolescent; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002822:Choriocarcinoma / Q000188:drug therapy; D003609:Dactinomycin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage*; D031901:Gestational Trophoblastic Disease / Q000188:drug therapy*; D006801:Humans; D002820:Hydatidiform Mole, Invasive / Q000188:drug therapy; D008875:Middle Aged; D011247:Pregnancy; D014594:Uterine Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
D000964:Antimetabolites, Antineoplastic; D005467:Floxuridine; D003609:Dactinomycin; D014750:Vincristine